The HNRNPDL Knockout HT29 Polyclonal Cells product represents a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, engineered for targeted disruption of the HNRNPDL gene. This loss-of-function model enables investigation of HNRNPDL-dependent post-transcriptional regulatory mechanisms in a well-characterized epithelial context. The polyclonal format provides a population-level knockout approach, facilitating studies of heterogeneous gene disruption effects across the cell population.
The HT29 host cell line is a widely utilized model of human colorectal adenocarcinoma, established as a prototypical intestinal epithelial cell system. HT29 cells display key features of colorectal cancer, including aberrant signaling pathways and dysregulated proliferation, and serve as a robust platform for examining oncogenic processes and epithelial biology. The availability of HNRNPDL knockout in this background offers a physiologically relevant system for dissecting RNA processing functions in colorectal cancer pathogenesis and intestinal epithelial homeostasis.
HNRNPDL encodes an RNA-binding protein that functions as a critical regulator of alternative splicing, mRNA stability, and nucleocytoplasmic transport. The protein is activated by cellular stress signals such as heat shock and oxidative stress, and phosphorylated by upstream kinases, integrating environmental cues to modulate downstream targets including apoptosis-related mRNAs and cell cycle regulators. HNRNPDL forms functional complexes with other hnRNP family members and spliceosomal components, thereby influencing the assembly and activity of the spliceosome and the expression of apoptosis effectors. Disruption of HNRNPDL expression consequently perturbs these multi-layered RNA regulatory networks.
In the context of HT29 cells, loss of HNRNPDL function may reveal novel insights into the post-transcriptional control of genes governing cell proliferation, apoptosis, and migration, processes frequently altered in colorectal cancer. Furthermore, because HNRNPDL mutations are linked to limb-girdle muscular dystrophy type 1G, this cell model provides a surrogate system to explore disease mechanisms beyond the intestinal epithelium, complementing in vivo and muscle cell-based studies. The knockout model thus bridges cancer biology and muscular dystrophy research within a single engineered platform.
This cell population is suited for diverse applications including mechanistic studies of RNA processing in colorectal cancer, validation of HNRNPDL as a potential drug target, and exploration of stress-responsive splicing alterations. Researchers can employ assays such as western blotting to confirm protein loss, RT-qPCR and RNA-seq for splicing analysis to assess transcriptome-wide changes, and functional assays measuring cell proliferation, apoptosis, and migration to evaluate phenotypic consequences of HNRNPDL disruption. For additional technical information, please contact Ascent Research.
